Venus Remedies Intrinsic Value
Venus Remedies intrinsic value. Venus Remedies (VENUSREM) median intrinsic value is ₹1185.94 from 10 valuation models (range ₹450–₹1689), vs current price ₹1501.60 — -21.0% downside (Trading Above Calculated Value), margin of safety -26.6%. For current market price and key ratios, visit Venus Remedies share price screener.
VENUSREM Valuation Methods Summary — DCF, Graham Number & P/E
Venus Remedies intrinsic value across 10 models vs current price ₹1501.60 — upside/downside and value range per method. Analyse VENUSREM shareholding pattern to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1688.72 | ₹1350.98 - ₹2026.46 | +12.5% | EPS: ₹76.76, Sector P/E: 22x |
| Book Value Method | asset | ₹1021.54 | ₹919.39 - ₹1123.69 | -32.0% | Book Value/Share: ₹510.77, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1347.69 | ₹1212.92 - ₹1482.46 | -10.2% | Revenue/Share: ₹673.85, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1323.08 | ₹1190.77 - ₹1455.39 | -11.9% | EBITDA: ₹172.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1630.00 | ₹1304.00 - ₹1956.00 | +8.6% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹491.26 | ₹442.13 - ₹540.39 | -67.3% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1185.94 | ₹1067.35 - ₹1304.53 | -21.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1120.00 | ₹1008.00 - ₹1232.00 | -25.4% | ROE: 15.7%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹939.23 | ₹845.31 - ₹1033.15 | -37.5% | EPS: ₹76.76, BVPS: ₹510.77 |
| Dividend Yield Method | dividend | ₹450.48 | ₹405.43 - ₹495.53 | -70.0% | DPS: ₹10.00, Target Yield: 2.5% |
VENUSREM Intrinsic Value vs Market Price — All Valuation Models
Venus Remedies fair value range ₹450–₹1689 vs current market price ₹1501.60 across 10 valuation models. Browse VENUSREM cash flow statement for revenue, profit, balance sheet and cash flow data.
VENUSREM Intrinsic Value Analysis — Undervalued or Overvalued?
Venus Remedies median intrinsic value ₹1185.94, current price ₹1501.60 — Trading Above Calculated Value by 21.0%, margin of safety -26.6%.
What is the intrinsic value of VENUSREM?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Venus Remedies (VENUSREM) is ₹1185.94 (median value). With the current market price of ₹1501.60, this represents a -21.0% variance from our estimated fair value.
The valuation range spans from ₹450.48 to ₹1688.72, indicating ₹450.48 - ₹1688.72.
Is VENUSREM undervalued or overvalued?
Based on our multi-method analysis, Venus Remedies (VENUSREM) appears to be trading above calculated value by approximately 21.0%.
VENUSREM Financial Health — Key Ratios vs Industry Benchmarks
Venus Remedies financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 15.7% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 19.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.03x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
VENUSREM Cash Flow Quality — Operating & Free Cash Flow
Venus Remedies operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹156 Cr | ₹64 Cr | Positive Free Cash Flow | 7/10 |
| March 2025 | ₹86 Cr | ₹48 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹37 Cr | ₹33 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹37 Cr | ₹8 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹41 Cr | ₹33 Cr | Positive Free Cash Flow | 8/10 |